Kymera Therapeutics KYMR 深 滬
等待開盤 08-13 09:30:00 美东时间
39.87
+2.190
+5.81%
華盛通- 最 高40.00
- 今 開37.82
- 成交量 93.98万股
- 最 低 37.57
- 昨 收 37.68
- 總市值 27.97亿
- 52周最高 53.27
- 市盈率 靜 --
- 換手率 1.34%
- 52周最低 19.445
- 委 比 -30.22%
- 總股本 7015.72万
- 歷史最高 91.92
- 量 比 1.18
- 振 幅 6.45%
- 歷史最低 9.60
- 每 手 1
- 風險率 9.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kymera Therapeutics Q2 EPS $(0.95) Misses $(0.84) Estimate, Sales $11.476M Miss $21.214M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.84) by 12.83 percent. This is a 63.79 percent decrease over losses of $(0.58) per share
08-11 19:04
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Kymera Therapeutics reported positive results for KT-621, an oral STAT6 degrader, with Phase 1 healthy volunteer data exceeding expectations. The Phase 1b trial in moderate to severe atopic dermatitis (AD) is on track to report data by year-end 2025, with Phase 2b trials in AD and asthma expected to begin next. The company also advanced KT-579, an oral IRF5 degrader, with IND-enabling studies ongoing. Additionally, Kymera entered a strategic part...
08-11 11:00
What to Expect from Kymera Therapeutics's Earnings
Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earni...
08-08 23:01
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
Kymera Therapeutics, a clinical-stage biotech company, will report its second-quarter 2025 financial results on August 11 and host a video conference call and webcast at 8:30 a.m. ET. The company specializes in developing oral small molecule degrader medicines for immunological diseases using targeted protein degradation technology. Interested parties can register via the provided links or visit the Investor section on the company’s website.
08-04 11:00
Gilead sees Q2 EPS hit from IPR&D expenses
Gilead Sciences (NASDAQ:GILD) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process research and development (IPR&D) charges, leading to a ~($0.04) reduction in...
07-12 06:23
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.
07-09 20:14
【国盛医药】周专题&周观点：从海外映射寻找下半年创新药新赛道
（转自：国医盛视） 一、医药核心观点 当周（6.30-7.04）回顾与周专题： 当周（6.30-7.04）申万医药指数环比+3.64%...
07-06 20:38
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
